drugset / Trial / NCT07512583
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Phase 1/2
Recruiting
178 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.
Timeline
- Start
- 2026-05-27
- Primary completion
- 2028-03
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2102 | Monoclonal antibody | — | Intravenous |
| Subject | TQB2930 | Unknown | — | Intravenous |